labetalol has been researched along with Cardiovascular Stroke in 30 studies
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Effects produced both by single intravenous drop-by-drop labetalol, 1 mg/kg (29 patients), sublingual obsidan, 20 mg (14 patients) and a 3-day course treatment with labetalol, 200-600 mg/day, and obsidan (80-160 mg/day) on systemic, intracardiac, and regional hemodynamics and oxygen supply of the body were comparatively studied in 43 patients in early periods of myocardial infarction." | 9.06 | [Effect of labetalol on hemodynamics and oxygen consumption in patients in the early period of myocardial infarction]. ( Gvatua, NA; Mironova, OV; Sirenko, IuN; Tolstopiatov, SM, 1990) |
| "The haemodynamic impact of alpha- and beta-adrenoceptor blockade (labetalol) was compared with that of slow-calcium channel blockade (nifedipine) in 32 patients with sustained elevation of systemic arterial pressure (systolic blood pressure greater than 160; diastolic blood pressure greater than 95 mmHg) following a recent myocardial infarction (6-22 h)." | 9.06 | Sympathetic (alpha-beta) or calcium channel blockade for hypertensive myocardial infarction? A haemodynamic comparison of labetalol and nifedipine. ( Hussain, M; Nelson, GI; Reynolds, GW; Richmond, A; Silke, B; Taylor, SH; Verma, SP; Wilson, JA, 1988) |
| "The haemodynamic consequences of combined alpha- and beta-adrenoceptor blockade with intravenous labetalol were evaluated in 21 males with either high (n = 6), normal (n = 9) or low (n = 6) systemic arterial pressure, 4-17 hours after acute myocardial infarction without heart failure." | 7.66 | Haemodynamic dose-response effects of intravenous labetalol in acute myocardial infarction. ( Ahuja, RC; Hussain, M; Nelson, GI; Silke, B; Taylor, SH, 1983) |
| "Labetalol was used to treat systemic hypertension (systolic blood pressure above 150 mmHg) in 11 patients with acute myocardial infarction; its haemodynamic effects and tolerance were studied." | 7.66 | Treatment of hypertension in acute stage of myocardial infarction. Haemodynamic effects of labetalol. ( Bernard, R; Jacobs, P; Renard, M; Rivière, A, 1983) |
| "1 The role of labetalol in managing acute myocardial infarction is reviewed." | 7.66 | Role of labetalol in acute myocardial infarction. ( Chamberlain, DA; Fowler, MB; Jaggarao, NS; Timmis, AD; Vincent, R, 1982) |
| "1 Fifteen patients with suspected acute myocardial infarction and systemic BP of greater than 160/110 mmHg were treated with an incremental infusion of labetalol." | 7.66 | Labetalol infusion in acute myocardial infarction with systemic hypertension. ( Marx, PG; Reid, DS, 1979) |
| "Pretreatment with propranolol or labetalol counteracted the appearance of the myocardial histological alterations and the associated ECG and biochemical lesions." | 5.32 | Isoproterenol-induced myocardial infarction in rabbits. Protection by propranolol or labetalol: a proposed non-invasive procedure. ( Accinni, R; Bonacina, E; Brenna, S; Pinelli, A; Tomasoni, L; Trivulzio, S, 2004) |
| "Effects produced both by single intravenous drop-by-drop labetalol, 1 mg/kg (29 patients), sublingual obsidan, 20 mg (14 patients) and a 3-day course treatment with labetalol, 200-600 mg/day, and obsidan (80-160 mg/day) on systemic, intracardiac, and regional hemodynamics and oxygen supply of the body were comparatively studied in 43 patients in early periods of myocardial infarction." | 5.06 | [Effect of labetalol on hemodynamics and oxygen consumption in patients in the early period of myocardial infarction]. ( Gvatua, NA; Mironova, OV; Sirenko, IuN; Tolstopiatov, SM, 1990) |
| "The haemodynamic impact of alpha- and beta-adrenoceptor blockade (labetalol) was compared with that of slow-calcium channel blockade (nifedipine) in 32 patients with sustained elevation of systemic arterial pressure (systolic blood pressure greater than 160; diastolic blood pressure greater than 95 mmHg) following a recent myocardial infarction (6-22 h)." | 5.06 | Sympathetic (alpha-beta) or calcium channel blockade for hypertensive myocardial infarction? A haemodynamic comparison of labetalol and nifedipine. ( Hussain, M; Nelson, GI; Reynolds, GW; Richmond, A; Silke, B; Taylor, SH; Verma, SP; Wilson, JA, 1988) |
| " The purpose of the present study was to investigate the haemodynamic, electrophysiological and antiarrhythmic effects of labetalol in the late reperfusion phase after myocardial infarction in conscious dogs." | 3.68 | Antiarrhythmic efficacy of labetalol as assessed by programmed electrical stimulation. ( Krejcy, K; Krumpl, G; Raberger, G; Todt, H, 1990) |
| "Paired bicycle ergometry [correction of veloergometric] testing was carried out in 94 patients with a history of myocardial infarction before and after single intakes of 40 mg of obsidan and 200 mg of labetalol." | 3.68 | [The use of labetalol and propranolol in patients who have had a myocardial infarct]. ( Babov, KD; Il'iash, MG; Kravtsova, LA; Shcherbak, IaIu, 1990) |
| "The comparative haemodynamic dose-response effects of beta- (propranolol) or alpha- plus beta-blockade (labetalol) were evaluated in a randomised between-group study of 16 patients with an uncomplicated acute myocardial infarction." | 3.67 | Comparison of haemodynamic dose-response effects of beta- and alpha-beta-blockade in acute myocardial infarction. ( Ahuja, RC; Nelson, GI; Silke, B; Taylor, SH; Walker, C, 1984) |
| "The antiarrhythmic and antifibrillatory actions of dilevalol, the R,R-isomer of labetalol, were evaluated in conscious dogs 4 to 6 days after anterior myocardial infarction." | 3.67 | Antifibrillatory efficacy of concomitant beta adrenergic receptor blockade with dilevalol, the R,R-isomer of labetalol, and muscarinic receptor blockade with methylscopolamine. ( Driscoll, EM; Lucchesi, BR; Lynch, JJ; MacEwen, SA; Nelson, SD, 1987) |
| "The haemodynamic consequences of combined alpha- and beta-adrenoceptor blockade with intravenous labetalol were evaluated in 21 males with either high (n = 6), normal (n = 9) or low (n = 6) systemic arterial pressure, 4-17 hours after acute myocardial infarction without heart failure." | 3.66 | Haemodynamic dose-response effects of intravenous labetalol in acute myocardial infarction. ( Ahuja, RC; Hussain, M; Nelson, GI; Silke, B; Taylor, SH, 1983) |
| "Labetalol was used to treat systemic hypertension (systolic blood pressure above 150 mmHg) in 11 patients with acute myocardial infarction; its haemodynamic effects and tolerance were studied." | 3.66 | Treatment of hypertension in acute stage of myocardial infarction. Haemodynamic effects of labetalol. ( Bernard, R; Jacobs, P; Renard, M; Rivière, A, 1983) |
| "1 The role of labetalol in managing acute myocardial infarction is reviewed." | 3.66 | Role of labetalol in acute myocardial infarction. ( Chamberlain, DA; Fowler, MB; Jaggarao, NS; Timmis, AD; Vincent, R, 1982) |
| "1 Fifteen patients with suspected acute myocardial infarction and systemic BP of greater than 160/110 mmHg were treated with an incremental infusion of labetalol." | 3.66 | Labetalol infusion in acute myocardial infarction with systemic hypertension. ( Marx, PG; Reid, DS, 1979) |
| " Labetalol caused lowering of the blood pressure and heart rate during the phase of intravenous treatment, but little effect occurred subsequently because oral dosage was constrained by low systolic pressures." | 2.66 | Effect of labetalol on indices of myocardial necrosis in patients with suspected acute infarction. ( Burwood, RD; Chamberlain, DA; Haskett, VL; Heber, ME; Lutkin, J; Rosenthal, E; Thomas, N; Vincent, R, 1987) |
| "Labetalol is a unique antihypertensive agent which is a competitive peripheral antagonist at both alpha- and beta-adrenoceptor sites." | 2.37 | Current status of labetalol, the first alpha- and beta-blocking agent. ( Kanto, JH, 1985) |
| "Pretreatment with propranolol or labetalol counteracted the appearance of the myocardial histological alterations and the associated ECG and biochemical lesions." | 1.32 | Isoproterenol-induced myocardial infarction in rabbits. Protection by propranolol or labetalol: a proposed non-invasive procedure. ( Accinni, R; Bonacina, E; Brenna, S; Pinelli, A; Tomasoni, L; Trivulzio, S, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 23 (76.67) | 18.7374 |
| 1990's | 4 (13.33) | 18.2507 |
| 2000's | 2 (6.67) | 29.6817 |
| 2010's | 1 (3.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zullo, AR | 1 |
| Hersey, M | 1 |
| Lee, Y | 1 |
| Sharmin, S | 1 |
| Bosco, E | 1 |
| Daiello, LA | 1 |
| Shah, NR | 1 |
| Mor, V | 1 |
| Boscardin, WJ | 1 |
| Berard-Collins, CM | 1 |
| Dore, DD | 1 |
| Steinman, MA | 1 |
| Pinelli, A | 1 |
| Trivulzio, S | 1 |
| Tomasoni, L | 1 |
| Brenna, S | 1 |
| Bonacina, E | 1 |
| Accinni, R | 1 |
| Chiariello, M | 1 |
| Brevetti, G | 1 |
| DeRosa, G | 1 |
| Acunzo, R | 1 |
| Petillo, F | 1 |
| Rengo, F | 1 |
| Condorelli, M | 1 |
| Johns, VJ | 1 |
| Mulac, KD | 1 |
| Meryn, S | 1 |
| Struthers, AD | 1 |
| Reid, JL | 1 |
| Nelson, GI | 4 |
| Silke, B | 4 |
| Ahuja, RC | 3 |
| Hussain, M | 2 |
| Taylor, SH | 4 |
| Bernard, R | 3 |
| Renard, M | 3 |
| Walker, C | 1 |
| Rivière, A | 1 |
| Jacobs, P | 2 |
| Choudhury, S | 1 |
| Glogar, DH | 2 |
| Kloner, RA | 1 |
| Zilcher, H | 1 |
| Weber, H | 1 |
| Kaindl, F | 1 |
| Timmis, AD | 2 |
| Fowler, MB | 2 |
| Jaggarao, NS | 2 |
| Vincent, R | 2 |
| Chamberlain, DA | 3 |
| Cantelli, I | 1 |
| Lombardi, G | 1 |
| Naccarella, F | 1 |
| Pavesi, PC | 1 |
| Bracchetti, D | 1 |
| Farhat, F | 1 |
| Loisance, D | 1 |
| Garnier, JP | 1 |
| Kirsch, M | 1 |
| Marx, PG | 1 |
| Reid, DS | 1 |
| Prichard, BN | 2 |
| Richards, DA | 1 |
| Gvatua, NA | 1 |
| Mironova, OV | 2 |
| Sirenko, IuN | 2 |
| Tolstopiatov, SM | 1 |
| Krumpl, G | 1 |
| Todt, H | 1 |
| Krejcy, K | 1 |
| Raberger, G | 1 |
| Il'iash, MG | 1 |
| Kravtsova, LA | 1 |
| Babov, KD | 1 |
| Shcherbak, IaIu | 1 |
| Kanto, JH | 1 |
| Lynch, JJ | 1 |
| Nelson, SD | 1 |
| MacEwen, SA | 1 |
| Driscoll, EM | 1 |
| Lucchesi, BR | 1 |
| Verma, SP | 1 |
| Wilson, JA | 1 |
| Reynolds, GW | 1 |
| Richmond, A | 1 |
| Ivanova, DK | 1 |
| Shkliar, LV | 1 |
| Liebens, I | 1 |
| Abou Hamdam, B | 1 |
| Debache, N | 1 |
| Bleinc, D | 1 |
| Touboul, A | 1 |
| Haquin, G | 1 |
| Chouty, F | 1 |
| Lardoux, H | 1 |
| Heber, ME | 1 |
| Rosenthal, E | 1 |
| Thomas, N | 1 |
| Haskett, VL | 1 |
| Burwood, RD | 1 |
| Lutkin, J | 1 |
3 reviews available for labetalol and Cardiovascular Stroke
| Article | Year |
|---|---|
Beta-blocking drugs for arrhythmias, hypertension, and ischemic heart disease.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Arrhythmias, Cardiac; Atenolol; Blood Pressur | 1984 |
Pharmacological and clinical aspects of drug therapy in coronary heart disease: clinical aspects of therapy with beta-adrenoceptor antagonists.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Coronary Disease; Hemodynamics; Humans | 1990 |
Current status of labetalol, the first alpha- and beta-blocking agent.
Topics: Adrenal Gland Neoplasms; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Anesthesia; Biot | 1985 |
5 trials available for labetalol and Cardiovascular Stroke
| Article | Year |
|---|---|
The haemodynamic effects of labetalol under conditions of increased levels of circulating catecholamines.
Topics: Blood Pressure; Epinephrine; Ethanolamines; Heart Rate; Humans; Labetalol; Myocardial Infarction | 1983 |
[Effect of labetalol on hemodynamics and oxygen consumption in patients in the early period of myocardial infarction].
Topics: Administration, Oral; Adult; Clinical Trials as Topic; Coronary Circulation; Hemodynamics; Humans; I | 1990 |
Sympathetic (alpha-beta) or calcium channel blockade for hypertensive myocardial infarction? A haemodynamic comparison of labetalol and nifedipine.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Calcium Channel Blockers; He | 1988 |
[Effect of obsidan and labetalol on the course of myocardial infarction].
Topics: Adult; Aged; Clinical Trials as Topic; Humans; Labetalol; Male; Middle Aged; Myocardial Infarction; | 1988 |
Effect of labetalol on indices of myocardial necrosis in patients with suspected acute infarction.
Topics: Aged; Blood Pressure; Coronary Circulation; Creatine Kinase; Female; Heart Rate; Humans; Isoenzymes; | 1987 |
22 other studies available for labetalol and Cardiovascular Stroke
| Article | Year |
|---|---|
Outcomes of "diabetes-friendly" vs "diabetes-unfriendly" β-blockers in older nursing home residents with diabetes after acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged, 80 and over; Blood Glucose; Carvedilol; Diabetes Mellitus, Type 2 | 2018 |
Isoproterenol-induced myocardial infarction in rabbits. Protection by propranolol or labetalol: a proposed non-invasive procedure.
Topics: Adrenergic beta-Antagonists; Animals; Electrocardiography; Isoproterenol; Labetalol; Lipid Peroxides | 2004 |
Protective effects of simultaneous alpha and beta adrenergic receptor blockade on myocardial cell necrosis after coronary arterial occlusion in rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Arterial Occlusive Diseases; Cor | 1980 |
Haemodynamic effects of intravenous labetalol in hypertensive patients with obstructive coronary heart disease complicated by acute myocardial infarction of recent origin.
Topics: Adult; Coronary Disease; Ethanolamines; Exercise Test; Female; Hemodynamics; Humans; Hypertension; I | 1983 |
Haemodynamic dose-response effects of intravenous labetalol in acute myocardial infarction.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Ethanolamines; Hemodynamics; Humans; | 1983 |
[Heart failure and acute myocardial infarct. Current treatment].
Topics: Cardiotonic Agents; Dobutamine; Heart Failure; Humans; Imidazoles; Labetalol; Myocardial Infarction; | 1983 |
Comparison of haemodynamic dose-response effects of beta- and alpha-beta-blockade in acute myocardial infarction.
Topics: Aged; Cardiac Output; Dose-Response Relationship, Drug; Ethanolamines; Heart Rate; Hemodynamics; Hum | 1984 |
Treatment of hypertension in acute stage of myocardial infarction. Haemodynamic effects of labetalol.
Topics: Adolescent; Adult; Aged; Drug Tolerance; Ethanolamines; Female; Hemodynamics; Humans; Hypertension; | 1983 |
Pharmacokinetic and haemodynamic studies with labetalol in acute myocardial infarction.
Topics: Blood Pressure; Cardiac Output; Ethanolamines; Hemodynamics; Humans; Labetalol; Male; Middle Aged; M | 1983 |
[Reduction of myocardial ischemia with labetalol in experimental myocardial infarct].
Topics: Animals; Collateral Circulation; Coronary Circulation; Dogs; Dose-Response Relationship, Drug; Ethan | 1981 |
Role of labetalol in acute myocardial infarction.
Topics: Acute Disease; Ethanolamines; Humans; Labetalol; Myocardial Infarction; Oxygen Consumption | 1982 |
[Hemodynamic effects of labetalol in patients with acute myocardial infarct and systemic arterial hypertension].
Topics: Adult; Aged; Ethanolamines; Female; Hemodynamics; Humans; Hypertension; Labetalol; Male; Middle Aged | 1981 |
Labetalol infusion for the treatment of hypertension in acute myocardial infarction.
Topics: Adult; Aged; Ethanolamines; Hemodynamics; Humans; Hypertension; Infusions, Parenteral; Labetalol; Ma | 1980 |
Norepinephrine release after acute brain death abolishes the cardioprotective effects of ischemic preconditioning in rabbit.
Topics: Animals; Brain Death; Coronary Disease; Disease Models, Animal; Female; Hemodynamics; Ischemic Preco | 2001 |
Labetalol infusion in acute myocardial infarction with systemic hypertension.
Topics: Adult; Electrocardiography; Ethanolamines; Female; Heart Rate; Hemodynamics; Humans; Hypertension; I | 1979 |
Labetalol, an alpha- and beta-adrenoceptor-blocking agent: its use in therapeutics. A summary of the symposium.
Topics: Administration, Oral; Anesthesia; Angina Pectoris; Catecholamines; Ethanolamines; Female; Hemodynami | 1979 |
Antiarrhythmic efficacy of labetalol as assessed by programmed electrical stimulation.
Topics: Animals; Anti-Arrhythmia Agents; Blood Pressure; Coronary Vessels; Dogs; Electric Stimulation; Elect | 1990 |
[The use of labetalol and propranolol in patients who have had a myocardial infarct].
Topics: Adult; Drug Evaluation; Exercise Test; Humans; Labetalol; Middle Aged; Myocardial Infarction; Physic | 1990 |
Antifibrillatory efficacy of concomitant beta adrenergic receptor blockade with dilevalol, the R,R-isomer of labetalol, and muscarinic receptor blockade with methylscopolamine.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Blood Pressure; Dogs; Electrocar | 1987 |
A comparison of the effects of combined or separate alpha- and beta-blockade in the treatment of hypertension in the acute stage of myocardial infarction.
Topics: Adult; Aged; Blood Pressure; Carbon Dioxide; Female; Heart Rate; Humans; Hypertension; Infusions, Pa | 1986 |
[Definition and significance of the area at risk in myocardial infarct and the ischemic border zone in acute myocardial infarct].
Topics: Animals; Collateral Circulation; Coronary Circulation; Coronary Disease; Dogs; Electrolytes; Energy | 1986 |
[Pheochromocytoma and myocardial infarction (apropos of a case in a 34-year-old man)].
Topics: Adrenal Gland Neoplasms; Adult; Humans; Hypertension; Labetalol; Male; Myocardial Infarction; Pheoch | 1986 |